Clinical data | |
---|---|
Trade names | Skytrofa |
Other names | Lonapegsomatropin-tcgd; rhGH-PEG; ACP-011; ΤransConPEG hGh; WHO-10598 |
License data | |
Routes of administration | Subcutaneous injection |
Drug class | Growth hormone receptor agonist |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem SID | |
DrugBank | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C1051H1627N269O317S9[C2H4O]4n |
Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency.[1][3] Lonapegsomatropin is a prodrug of somatropin.[1]
Lonapegsomatropin was approved for medical use in the United States in August 2021,[1][2][5] and in the European Union in January 2022.[3]